SITC 2021 | CAMILLA: Combining a VEGF TKI with immune checkpoint inhibitors for GE and GI cancer

Anwaar Saeed, MD, University of Kansas Medical Center, Kansas City, MO, discusses the rationale behind the CAMILLA trial (NCT03539822), which investigated the combination of cabozantinib, a tyrosine kinase inhibitor (TKI), with durvalumab, a PD-L1 inhibitor, in patients with gastric cancer, esophageal adenocarcinoma, hepatocellular carcinoma, and colorectal cancer. The trial focused on patients with stage 3 and 4 microsatellite-stable disease. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.